Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

References

• JohnsonKPDueDLBenefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosisExpert Rev Pharmacoecon Outcomes Res20099320521419527092
   PubMedGoogle Scholar
• RudickRAPolmanCHCurrent approaches to the identification and management of breakthrough disease in patients with multiple sclerosisLancet Neurol20098654555919446274
   PubMed Web of Science ®Google Scholar
• BergerJRHouffSOpportunistic infections and other risks with newer multiple sclerosis therapiesAnn Neurol200965436737719399841
   PubMed Web of Science ®Google Scholar
• SchweikertAKremerMRingelFPrimary central nervous system lymphoma in a patient treated with natalizumabAnn Neurol200966340340619798640
   PubMed Web of Science ®Google Scholar
• SørensenPSDeisenhammerFDudaPGuidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosisEur J Neurol2005121181782716241970
   PubMed Web of Science ®Google Scholar
• HesseDSellebjergFSorensenPSAbsence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivityNeurology200973537237719652141
   PubMed Web of Science ®Google Scholar
• De StefanoNFilippiMConfavreuxCThe results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosisMult Scler200915223824318987103
   PubMed Web of Science ®Google Scholar
• ArnonRThe development of Cop 1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis: Personal reflectionsImmunol Lett1996501–21158793553
   PubMed Web of Science ®Google Scholar
• SchrempfWZiemssenTGlatiramer acetate: Mechanisms of action in multiple sclerosisAutoimmun Rev20076746947517643935
   PubMed Web of Science ®Google Scholar
• BlanchetteFNeuhausOGlatiramer acetate: evidence for a dual mechanism of actionJ Neurol20082551 Suppl263618317674
   PubMedGoogle Scholar
• AharoniRKayhanBEilamRSelaMArnonRGlatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situProc Natl Acad Sci U S A20031002 Suppl141571416214614135
   PubMedGoogle Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trialNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• FordCCJohnsonKPLisakRPA prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patientsMult Scler200612330932016764344
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 ug or 500 ug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
   PubMed Web of Science ®Google Scholar
• CadavidDWolanskyLJSkurnickJEfficacy of treatment of MS with IFNB-1b or glatiramer acetate by monthly brain MRI in the BECOME studyNeurol200919761983
   PubMedGoogle Scholar
• ComiGMartinelliVRodegherMEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet20093741503151119815268
   PubMed Web of Science ®Google Scholar
• RoccaMAComiGCarraATreatment with glatiramer acetate reduces T1 and T2-weighted magnetic resonance imaging activity in patients with clinically isolated syndrome suggestive of multiple sclerosisMult Scler200814S29S293 [P501].
   Web of Science ®Google Scholar
• ArnoldDLNarayananSAntelSTreatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trialMult Scler2008141S5S27
   Google Scholar
• FordCJohnsonKKachuckNContinuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMult Scler200814S29S293 [P44].
   Google Scholar
• GauthierSAGlanzBIMandelMIncidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort studyJ Neurol Sci20092841–211611919428028
   PubMed Web of Science ®Google Scholar
• CohenBAKhanOJefferyDRIdentifying and treating patients with suboptimal responsesNeurology20046312 Suppl 6S33S4015623669
   PubMed Web of Science ®Google Scholar
• FarrellRAGiovannoniGMeasuring and management of anti-interferon beta antibodies in subjects with multiple sclerosisMult Scler200713556757717548434
   PubMedGoogle Scholar
• CostelloKKennedyPScanzilloJRecognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long termMedscape J Med200810922519008986
   PubMedGoogle Scholar
• HaasJFirzlaffMTwenty-four-month comparison of immunomodulatory treatments – A retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)Eur J Neurol200512642543115885045
   PubMed Web of Science ®Google Scholar
• Copaxone [package insert]Teva NeuroscienceKansas City, MO U S A 64131, 2009
   Google Scholar
• CaonCDinMChingWTselisALisakRKhanOClinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosisEur J Neurol200613547147416722971
   PubMed Web of Science ®Google Scholar
• CarráAOnahaPLueticGTherapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsingremitting multiple sclerosis in ArgentinaEur J Neurol200815438639318353125
   PubMed Web of Science ®Google Scholar
• ZwibelHLGlatiramer acetate in treatment-naïve and prior interferon-β-1b-treated multiple sclerosis patientsActa Neurol Scand2006113637838616674604
   PubMed Web of Science ®Google Scholar
• ZiemssenTMultiple sclerosis beyond EDSS: depression and fatigueJ Neurol Sci20092771 SupplS37S4119200865
   PubMed Web of Science ®Google Scholar
• DennettSLCastelli-HaleyJOleen-BurkeyMThe Impact of Multiple Sclerosis on Patient Employment: a Review of the Medical LiteratureJ Health Productivity2007101218
   Google Scholar
• FiskJDPontefractARitvoPGArchibaldCJMurrayTJThe impact of fatigue on patients with multiple sclerosisCan J Neurol Sci19942119148180914
   PubMed Web of Science ®Google Scholar
• ZiemssenTHoffmanJApfelRKernSEffects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosisHealth Qual Life Outcomes200866718775064
   PubMed Web of Science ®Google Scholar
• FrealJEKraftGHCoryellJKSymptomatic fatigue in multiple sclerosisArch Phys Med Rehabil19846531351386703889
   PubMed Web of Science ®Google Scholar
• SmithMMArnettPAFactors related to employment status changes in individuals with multiple sclerosisMult Scler200511560260916193900
   PubMed Web of Science ®Google Scholar
• HeesenCNawrathLReichCFatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?J Neurol Neurosurg Psychiatry2006771343916361589
   PubMed Web of Science ®Google Scholar
• ZiemssenTKümpfelTKlinkertWEFNeuhausOHohlfeldRGlatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapyBrain2002125112381239112390966
   PubMedGoogle Scholar
• PattenSBBeckCAWilliamsJVABarbuiCMetzLMMajor depression in multiple sclerosis: A population-based perspectiveNeurology200361111524152714663036
   PubMed Web of Science ®Google Scholar
• SadovnickADRemickRAAllenJDepression and multiple sclerosisNeurology19964636286328618657
   PubMed Web of Science ®Google Scholar
• FeinsteinAAn examination of suicidal intent in patients with multiple sclerosisNeurology200259567467812221156
   PubMed Web of Science ®Google Scholar
• TsaiSGlatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effectsMed Hypotheses200769114514817196755
   PubMed Web of Science ®Google Scholar
• ZiemssenTSchrempfWGlatiramer acetate: mechanisms of action in multiple sclerosisInt Rev Neurobiol20077953757017531858
   PubMed Web of Science ®Google Scholar
• ZiemssenTReichmannHSchneiderHPresence of glatiramer acetate-specific TH2 cells in the cerebrospinal fluid of patients with multiple sclerosis 12 months after the start of therapy with glatiramer acetateJ Neurodegen Regen200811922
   Google Scholar
• VarkonyHWeinsteinVKlingerEThe glatiramoid class of immunomodulator drugsExpert Opin Pharmacother200910465766819245345
   PubMed Web of Science ®Google Scholar
• CohenJARovarisMGoodmanADLadkaniDWynnDFilippiMRandomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MSNeurology2007681293994417372130
   PubMed Web of Science ®Google Scholar
• ComiGCohenJAFilippiMResults from a phase III, one-year, randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-remitting multiple sclerosisSession Presentation: World Congress on Treatment and Research in Multiple SclerosisMontreal, Canada [P79]. 2008 September 17–20
   Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• NgCYMadsenJCRosengardBRAllanJSImmunosuppression for lung transplantationFront Biosci2009141627164119273152
   PubMed Web of Science ®Google Scholar
• CookSVermerschPComiGSafety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY studySession Presentation: 25th Congress of the European Committee for Treatment and Research in Multiple SclerosisDusseldorf, Germany [88]. 2009 September 9–12
   Google Scholar
• KapposLCohenJPelletierJon behalf of the TRANSFORMS (TRial Assessing injectable interferoN vs FTY720 Oral in RRMS) Study GroupSafety findings from a 12-month phase III study (TRANSFORMS) comparing oral fingolimod (FTY720) and intramuscular interferon beta-1a for relapsing-remitting multiple sclerosisPoster Presentation: 25th Congress of the European Committee for Treatment and Research in Multiple SclerosisDusseldorf, Germany [P807]. 2009 September 9–12
   Google Scholar
• FishmanJAInfection in solid-organ transplant recipientsN Engl J Med2007357252601261418094380
   PubMed Web of Science ®Google Scholar
• KawasakiHCarreraCJPiroLDSavenAKippsTJCarsonDARelationship of deoxycytidine kinase and cytoplasmic 5’-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosineBlood19938135976018094016
   PubMed Web of Science ®Google Scholar
• RobakTBlonskiJZGora-TyborJCladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)Blood2006108247347916551966
   PubMed Web of Science ®Google Scholar
• RobakTBłońskiJZKasznickiMCladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – Updated results of the multicentre study of 378 patientsBr J Haematol2000108235736810691866
   PubMed Web of Science ®Google Scholar
• MartinMGWelchJSAugustinKHladnikLDiPersioJFAbboudCNCladribine in the treatment of acute myeloid leukemia: a single-institution experienceClin Lymphoma Myeloma20099429830119717379
   PubMedGoogle Scholar
• HirotaYYoshiokaATanakaSImbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cellsCancer Res19894949159192563234
   PubMed Web of Science ®Google Scholar
• CarsonDAWassonDBTaetleRYuASpecific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood19836247377436136305
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSKoziolJAMcmillanRZyroffJThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A1996934171617208643695
   PubMed Web of Science ®Google Scholar
• ChesonBDInfectious and immunosuppressive complications of purine analog therapyJ Clin Oncol1995139243124487666104
   PubMed Web of Science ®Google Scholar
• LeistTPVermerschPThe potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulationCurr Med Res Opin200723112667267617880754
   PubMed Web of Science ®Google Scholar
• RiceGPAFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trialNeurology20005451145115510720289
   PubMed Web of Science ®Google Scholar
• SipeJCCladribine for multiple sclerosis: review and current statusExp Rev Neurother200556721727
   PubMedGoogle Scholar
• BrousilJARobertsRJSchleinALCladribine: an investigational immunomodulatory agent for multiple sclerosisAnn Pharmacother200640101814182116985095
   PubMed Web of Science ®Google Scholar
• CostelloKSipeJCCladribine tablets’ potential in multiple sclerosis treatmentJ Neurosci Nurs200840527528018856248
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSDResults from the CLARITY study: a phase III randomized, double-blind study to evaluate the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis (RRMS)Session Presentation: 61st Annual Meeting of the American Academy of NeurologySeattle, WA [Abstract LBS.001]. 2009 April 25–May 2
   Google Scholar
• GiovannoniGComiGCookSfor the CLARITY Study GroupA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med Published at NEJM.org 1202010 (DOI: 10.1056/NEJMoa0909494).
   PubMed Web of Science ®Google Scholar
• Merck Serono submits application for cladribine tablets as a potential oral short-course multiple sclerosis therapy in the United States [press release]. Merck Serono; 2009930
   Google Scholar
• RomineJSSipeJCKoziolJAZyroffJBeutlerEA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians1999111135449893155
   PubMedGoogle Scholar
• The Multiple Sclerosis Resource CentreEU asked to approve oral multiple sclerosis treatment, cladribine200993 http://msrc.co.uk/index.cfm?fuseaction=show&pageid=1629 Accessed October 1, 2009.
   Google Scholar
• ColesAJCoxALe PageEThe window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyJ Neurol200625319810816044212
   PubMed Web of Science ®Google Scholar
• MuraroPABielekovaBEmerging therapies for multiple sclerosisNeurotherapeutics20074467669217920549
   PubMed Web of Science ®Google Scholar
• MoreauTThorpeJMillerDPreliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosisLancet199434489182983017914262
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial InvestigatorsColesAJCompstonDAAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• ColesAAlemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 yearsPoster Presentation: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis [P890]. Dusseldorf, Germany2009 September 9–12
   Google Scholar
• Rituxan [package insert]South San Francisco, CA USA 94080, 992009
   Google Scholar
• CrossAHStarkJLLauberJRamsbottomMJLyonsJRituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJ Neuroimmunol20061801–2637016904756
   PubMed Web of Science ®Google Scholar
• WaubantESpotlight on Anti-CD20Int MS J200815192518713565
   PubMedGoogle Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• CarsonKREvensAMRicheyEAProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood2009113204834484019264918
   PubMed Web of Science ®Google Scholar
• BuddeKSchu̇tzMGlanderPFTY720 (fingolimod) in renal transplantationClin Transplant20062017 Suppl172417100697
   PubMedGoogle Scholar
• MandalaSHajduRBergstromJAlteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonistsScience2002296556634634911923495
   PubMed Web of Science ®Google Scholar
• KahanBDKarlixJLFergusonRMPharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I studyTransplantation20037671079108414557756
   PubMed Web of Science ®Google Scholar
• ChoiJWHerrDLeeCWTeoSKennedyGChunJS1P1 receptor signalling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and the efficacy of fingolimod (FTY720)Session Presentation: World Congress on Treatment and Research in Multiple SclerosisMontreal, Canada [P29]. 2008 September 17–20
   Google Scholar
• ForrestMSunSHajduRImmune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypesJ Pharmacol Exp Ther2004309275876814747617
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med20063551124114016971719
   PubMed Web of Science ®Google Scholar
• O’ConnorPMontalbanXAntelJOral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension studyNeurol2009727379
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPfor the FREEDOMS Study GroupOral fingolimod (FTY720) in patients with relapsing multiple sclerosis: 3-year results from a phase II study extensionPoster Presentation: World Congress on Treatment and Research in Multiple SclerosisMontreal, Canada [P72]. 2008 September 17–20
   Google Scholar
• CohenJBarkhofFComiGfor the TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Published at NEJM.org January 20, 2010 (10.1056/NEJMoa0907839).
   Google Scholar
• Novartis Pharmaceutical Corporation First phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a [press release]. Novartis; 2008 December 12.
   Google Scholar
• KapposLRadueEWO’ConnorPfor the FREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med Published at NEJM.org January 20, 2010 (10.1056/NEJMoa0909494).
   Web of Science ®Google Scholar
• TallantyreEEvangelouNConstantinescuCSSpotlight on teriflunomideInt MS J2008152626818782502
   PubMedGoogle Scholar
• O’ConnorPWLiDFreedmanMSA phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• FreedmanMWolinskyJSByrnesWJOral teriflunomide or placebo added to interferon beta for 6 months in patients with relapsing multiple sclerosis: safety and efficacy resultsPoster Presentation: 25th Congress of the European Committee of Treatment and Research in Multiple Sclerosis [P878]. Dusseldorf, Germany2009 September 9–12
   Google Scholar
• Arava [package insert]. sanofi-aventis US LLC, Bridgewater, NJ 08807 USA, 2009
   Google Scholar
• NoseworthyJHWolinskyJSLublinFDLinomide in relapsing and secondary progressive MS: part I: trial design and clinical resultsNeurology20005491726173310802775
   PubMed Web of Science ®Google Scholar
• TanILLycklamaÀNijeholtGJPolmanCHAdèrHJBarkhofFLinomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trialsMult Scler2000629910410773855
   PubMed Web of Science ®Google Scholar
• WolinskyJSNarayanaPANoseworthyJHLinomide in relapsing and secondary progressive MS: Part II: MRI resultsNeurol20005417341741
   PubMed Web of Science ®Google Scholar
• BrunmarkCRunströmAOhlssonLThe new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJ Neuroimmunol20021301–216317212225898
   PubMed Web of Science ®Google Scholar
• JönssonSAnderssonGFexTSynthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationshipJ Med Chem20044782075208815056005
   PubMed Web of Science ®Google Scholar
• ZouLPAbbasNVolkmannISuppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissueNeuropharmacology200242573173911985832
   PubMed Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMLindeANordleONedermanTTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• ComiGAbramskyOArbizuTOral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multi-center, randomized, double-blind, parallel-group placebo-controlled studyMult Scler200814S37
   Google Scholar
• ComiGAbramskyOArbizuTfor the LAQ/5062 Clinical Advisory Board and Study GroupLong-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favourable safety and sustained low relapse rate and MRI activityPoster Presentation: 25th Congress of the European Committee for Treatment and Research in Multiple SclerosisDusseldorf, Germany [P443]. 2009 September 9–12
   Google Scholar
• RollAReichKBöerAUse of fumaric acid esters in psoriasisIndian J Dermatol Venereol Leprol200773213313717456929
   PubMed Web of Science ®Google Scholar
• LinkerRALeeDHStangelMGoldRFumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studiesExp Rev Neurother200881116831690
   PubMedGoogle Scholar
• HöxtermannSNüchelCAltmeyerPFumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasisDermatology199819622232309568412
   PubMed Web of Science ®Google Scholar
• TreumerFZhuKGläserRMrowietzUDimethylfumarate is a potent inducer of apoptosis in human T cellsJ Invest Dermatol200312161383138814675187
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baselinecontrolled pilot studyEur J Neurol200613660461016796584
   PubMed Web of Science ®Google Scholar
• GoldRKapposLMillerDHSafety profile of BG00012, an oral formulation of dimethyl fumarate for patients with relapsing MSPoster Presentation: World Congress on Treatment and Research in Multiple SclerosisMontreal, Canada [P50]. 2008 September 17–20
   Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar